

:  
\*

83/11/24 : \_ 83/10/5 :

## Comparison of Vaginal Suppository and Intravenous PGE2 in Termination of Missed Abortion in First Trimester

### Abstract:

**Objective:** There are several methods for abortion either surgical or medical, and one of them is usage of prostaglandin. In purpose of comparing the effect and complication of vaginal suppository and IV PGE2 in termination of missed abortions in first trimester this study was done.

**Materials & Methods:** This case-control study was done on 74 patients in Beheshti Hospital of Isfahan during 2002-2003. Indication for termination of pregnancy was missed abortion in the first trimester. Patient was divided randomly into two equal groups. In first group 5mg of PGE2 was applied (diluted in 1000cc 5% dextrose serum) and according to necessity, the dosage of this drug was increased. In second group two vaginal suppositories PGE2 (3mg) were administered. Simultaneously, oxytocin (30 IU) was administered. Then results of two groups were compared with t-test (SPSS-10).

**Results:** Patients of two groups were identical (age, gestational age, parity). Frequency of complete abortion in IV PGE2 group was significantly more than vaginal PGE2 group. (11 patient (29%), 3] patient (8%) respectively,  $p < 0.001$ ) Duration from induction to expulsion of fetus in IV PGE2 group was significantly less than vaginal PGE2 group. (9.3+3) hours against 13.2+5.8 hours and  $p < 0.001$ ). In 5 patients (13%) of IV PGE2 group complications were detected, but no complications were detected in vaginal PGE2 group.

**Conclusion:** Efficacy of IV PGE2 in induction of abortion is better than vaginal PGE2 and has no serious complications.

**Key Words:** Termination of Pregnancy, PGE2 , Vaginal Suppository , IV Infusion.



E2

(8)

(9)

30

90

(1)

(2)

(5)

E2

(7)

(3)

(6)

(4)

E2

1960

E2

(5)

74

(6)

81 82

E2

20

E2

(5 7)

20

28 13

1 1/88

4

(LMP)

13 ± 3/5

37

13/8 ± 3/8

E2

8/9 ± 3/1

9/2 ± 3/2

5

5

0/5

%100

1

(%29) 11

E2

3

(%8) 3

(1) (P<0/001)

30

E2

1

74

1381 1382

%29	%100	E2
%8	%100	E2

1383

SPSS 10

3 9/3± 3 E2

26/8

14

38

17

E2



( 1382 ) 27 4 13/2+5/8  
 . (10) %100 . (P<0/001)  
 ( 2000 Witter )  
 %20 25  
 %2/7 10 (%5/4) (%2/7)  
 .(11) (%2/7)  
 . (%8/1) 3  
 . %13  
 %29 E2  
 %8 E2 . ( 2 )  
 - 2  
 E2  
 74  
 . ( 1379 ) 1381 1382  
 %83  
 %85  
 . (12)  
 ( 1382 )  
 (%11/1 %77/8)  
 ( 1992 owen ) . (10)  
 %20 28 %13 18  
 E2  
 . (13)  
 %20 50  
 2 3  
 .(14) %100 ( )

%8/1	%2/7	%5/4	2/7 %	0	E2
0	0	0	0	0	E2

(9)

E2

9/3±3)

(P<0/001

13/2±5/8

(1382)

(10)

(14)

%30 60

E2

(1992 Owen)

(2004, Luckas)

I

(9 13)

)

(E2

72 20

(16)

1

E2

15

(15)

E2

(%13)

5

%11/1

(1382)

%44/4


(2004 Luckas)

(10)

%40

1383





**References :**

- 1) el-Rafaey H, Calder L, Wheatley DN, et al. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. *Lancet* 1994 May 14;343(8907):1207-9 .
- 2) el-Rafaey H, Rajasekar D, Abdalla M, et al. Induction of abortion with mifepristone (RU486) and oral or vaginal misoprostol .*N Engl J Med* .1995 Apr 13;332(15):983-7.
- 3) Johnson N. Intracervical tents: usage and mode of action. *Obstet Gynecol Surv* 1989 Jun; 44(6):410-20 .
- 4) Gupta JK, Johnson N. Should we use prostaglandins, tents or progesterone antagonists for cervical ripening before first trimester abortion?. *Contraception* 1992 Nov; 46(5) :489-97.
- 5) Stitely ML, Satin AJ. Cervical ripening agents and uterine stimulants. *Clin Obstet Gynecol* 2002 Mar; 45(1):114-24.
- 6) Prins RP, Neilson DR Jr, Bolton RN, et al. Preinduction cervical ripening with sequential use of prostaglandin E2 gel .*Am J Obstet Gynecol* 1986 Jun; 154(6):1275-9.
- 7) Irion O, Pedrazzoli J, Mermillod B. A randomized trial comparing vaginal and cervical prostaglandin gel for cervical ripening and labor induction. *Obstet Gynecol* .1998 Jan; 91(1):65-7

- 8) Zhou W, Sorensen HT, Olsen J. Induced abortion and subsequent pregnancy duration. *Obstet Gynecol* 1999; 94:948 .
- 9) Luckas M, Bricker L. Intravenous prostaglandin for induction of labor. *Cochrane Database syst Rev* 2000; 4: CD0002864.  
E2 (10
- .62 58 :(1382 )27
- 11) Witter FR. Prostaglandin E2 preparations for preinduction cervical ripening. *Clin Obstet Gynecol* 2000 Sep; 43(3):469-74 .  
E2 (12
- 9 :(1379 )4 .14
- 13) Owen J, Hauth JC, Winkler CL, et al. Midtrimester pregnancy termination: a randomized trial of prostaglandin E2 versus concentrated oxytocin .*Am J Obstet Gynecol* 1992 Oct; 167(4):1112-6.
- 14) Ramsey PS, Owen J. Midtrimester cervical ripening and labor induction. *Clini Obstet Gynecol* 2000; 43(3):495-512.
- 15) Termination of early pregnancy. *Abortion practical guide for doctors*. 2002 Feb; P.22.
- 16) ML Foegh, M Hecker, PW Ramwell. The eicosanoids: prostaglandins, thromboxanes, leukotrienes and related compounds. In: *Katzung BG. Basic & Clinical Pharmacology*. New York: Appleton &Lang; 1998: 304-17.

